Enveric Biosciences(US:ENVB)2026-03-27 21:25Financial Performance - Enveric reported a net loss of $4.0 million for Q4 2025, with a basic and diluted loss per share of $6.12, compared to a net loss of $3.2 million and a loss per share of $58.06 in Q4 2024[10]. - The company raised gross proceeds of $12.2 million through offerings for the fiscal year 2025[10]. - In January 2026, Enveric raised approximately $1.5 million from a registered direct offering[11]. - The company completed a reverse stock split on October 28, 2025, at a ratio of 1 post-split share for every 12 pre-split shares[12]. Drug Development - Positive preclinical results for lead drug candidate EB-003 showed statistically significant improvements in animal models of severe chronic depression and PTSD[3]. - The FDA allowed for streamlined plans for the IND submission of EB-003, with successful completion of pre-IND dose range finding studies[7]. - The company is preparing for a first-in-human Phase 1 clinical trial for EB-003, targeting both 5-HT2A and 5-HT1B receptors[4]. - Enveric's research confirmed EB-003's dual-mechanism of action, promoting neuroplasticity without hallucinogenic effects[2]. Intellectual Property - Enveric's intellectual property portfolio was strengthened with multiple patents and notices of allowance for the EVM301 and EVM401 Series of compounds[12]. Corporate Strategy - The company relocated its corporate headquarters to Cambridge, MA, to leverage the Greater Boston biotech hub[12].